SUPN Stock Summary and Trading Ideas (Supernus | NASDAQ:SUPN)

Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.

Supernus trades on the NASDAQ stock market under the symbol SUPN.

As of November 11, 2026, SUPN stock price climbed to $29.23 with 905,179 million shares trading.

SUPN has a beta of 1.36, meaning it tends to be more sensitive to market movements. SUPN has a correlation of 0.15 to the broad based SPY ETF.

SUPN has a market cap of $1.70 billion. This is considered a Small Cap stock.

Last quarter Supernus reported $227 million in Revenue and $.35 earnings per share. This beat revenue expectation by $8 million and missed earnings estimates by -$.11.

In the last 3 years, SUPN traded as high as $59.68 and as low as $25.53.

The top ETF exchange traded funds that SUPN belongs to (by Net Assets): IJR, IWM, VTI, SPSM, IJT.

SUPN has underperformed the market in the last year with a price return of -17.7% while the SPY ETF gained +12.7%. SUPN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.6% and -8.8%, respectively, while the SPY returned -1.4% and -1.2%, respectively.

SUPN support price is $27.81 and resistance is $29.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SUPN shares will trade within this expected range on the day.